Active Surveillance Studies
Evaluate the probability and frequency of adverse events as part of post-marketing risk assessment for medical products.

Want to learn more?

Overview

Regulatory agencies worldwide seek to reduce the impact of adverse events in financial and humanistic terms. We conduct post-authorization safety studies (PASS) to investigate the frequency of already known adverse events and possible rare adverse events in a patient population that is typical of real-life users. ZEG Berlin, a Kantar Company, developed the EURAS/INAS study design, which has been internationally recognized as being scientifically and methodically robust.

Global scope

60 global epidemiology studies
300 published pieces in peer-reviewed journals
15 million subjects worldwide

Key features

Robust methodology in risk/benefit assessment

We question participants directly at baseline and follow-ups, to spot co-variables you won't find anywhere else.

Regulatory acceptance

The EURAS/INAS study design is recognized as effective in risk assessment in the post-marketing environment.

Pioneering expertise

We have a proven record in global active safety surveillance and pharmacoepidemiology programs under the ENCePP seal.

Quality Standards

Learn more about our commitment to quality.
Read more

Clinical Publications

Over 1,500 scientific and peer-reviewed articles to further understanding in health research.
Read more
Related solutions
Data and evidence for a comprehensive view of patients, globally.